Skip to main content

xerava

Generic: eravacycline·Brand: XERAVA, Xerava

xerava: sourced relationships with 2 companies · 1 clinical trial tracked · 1 FDA decision.

xerava evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

What is verified about xerava, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

complicated intra-abdominal infections (cIAI)

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
LA JOLLA PHARMACEUTICAL CO (LJPC)
licensee · Reported 2021-03-08 · Current development: unknownSource
complicated intra-abdominal infections (cIAI)
Approved
TETRAPHASE PHARMACEUTICALS INC (TTPH)
developer · Reported 2020-03-12 · Current development: unknownSource
complicated intra-abdominal infections (cIAI)
Approved
Clinical Trial Registry Records (1)

Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Intravenous Eravacycline in Pediatric Patients From 8 Years to Less Than 18 Years of Age With Complicated Intra-abdominal Infections (cIAI)

NCT06794541Registry updated 2025-10-29·Phase 2·TTPH
Recruiting

Primary endpoint: Proportion of patients with Adverse Events (AEs) from the first dose of any amount of eravacycline

Interventionalopen35 targetStarted 2025-05Completion 2029-035 sites · United StatesTetraphase Pharmaceuticals, Inc
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra‑abdominal infections in patients 18 years of age and older. ( 1.1 ) Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI). ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are prove(TTPH)FDA ↗
NDA211109Type 1 - New Molecular EntityPriorityIntravenousPowder

Frequently asked questions

Which companies have sourced relationships with xerava?

xerava has dated SEC/FDA relationship records for LA JOLLA PHARMACEUTICAL CO, TETRAPHASE PHARMACEUTICALS INC.

How many clinical trials involve xerava?

BioSniper tracks 1 clinical trial involving xerava.

What is xerava's latest FDA decision?

The most recent tracked FDA decision for xerava is Approval for 1 INDICATIONS AND USAGE XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra‑abdominal infections in patients 18 years of age and older. ( 1.1 ) Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI). ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are prove, dated August 27, 2018.